Mersadon is involved in the development of the new crown vaccine through acquisitions and cooperation. U.S. drugmaker Mercado plans to buy Austrian vaccine maker Themis Bioscience and will work with non-profit research firm IAVI to develop the vaccine, Reuters reported on May 26. At the same time, Mercado also announced a partnership with biotech company Ridgeback Biopros to develop an antiviral drug to treat new coronary pneumonia.
Merck Sharp and Dohme, MSD is one of the world’s largest pharmaceutical companies, headquartered in Kenilworth, N.J. In the U.S. and Canada, Mercado is also known as Merck and Co Inc.
The Themis Bioscience, to be acquired by Mercado, is working with the Pasteur Institute in Paris to develop a new coronary pneumonia vaccine based on an improved measles virus. Mr Mercadon said volunteers would be vaccinated within weeks.
IAVI’s vaccine technology is similar to That’s, which was recently approved by the European Commission and the U.S. Food and Drug Administration. The vaccine, developed with IAVI, will be tested in humans this year, According to Mercado.
According to Reuters, Theis’s vaccine is already under going into clinical trials in France. Mercadon plans to begin production of vaccines developed in collaboration with IAVI at its Pennsylvania plant.
However, kenneth Frazier, chief executive of Mersadon, questioned the time frame for developing an effective new coronavirus vaccine within 12 to 18 months, describing the widely discussed schedule as “very radical”, the Financial Times reported on May 27. Mr Fraser’s comments come less than two weeks after the US government launched Operation Warp Speed, which seeks to significantly reduce the time it takes to develop a vaccine.
Reuters reports that more than 100 vaccines for new coronary pneumonia are currently under development, 12 of which are being tested in humans to assess their safety.